JP2024041873A5 - - Google Patents

Download PDF

Info

Publication number
JP2024041873A5
JP2024041873A5 JP2024001623A JP2024001623A JP2024041873A5 JP 2024041873 A5 JP2024041873 A5 JP 2024041873A5 JP 2024001623 A JP2024001623 A JP 2024001623A JP 2024001623 A JP2024001623 A JP 2024001623A JP 2024041873 A5 JP2024041873 A5 JP 2024041873A5
Authority
JP
Japan
Prior art keywords
cells
cancer
population
specific
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2024001623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024041873A (ja
JP7728373B2 (ja
Filing date
Publication date
Priority claimed from JP2020544357A external-priority patent/JP7054418B2/ja
Application filed filed Critical
Publication of JP2024041873A publication Critical patent/JP2024041873A/ja
Publication of JP2024041873A5 publication Critical patent/JP2024041873A5/ja
Application granted granted Critical
Publication of JP7728373B2 publication Critical patent/JP7728373B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2024001623A 2017-11-08 2024-01-10 T細胞を製造する組成物及び方法 Active JP7728373B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201762583229P 2017-11-08 2017-11-08
US62/583,229 2017-11-08
US201762588590P 2017-11-20 2017-11-20
US62/588,590 2017-11-20
US201862618445P 2018-01-17 2018-01-17
US62/618,445 2018-01-17
US201862737625P 2018-09-27 2018-09-27
US62/737,625 2018-09-27
JP2020544357A JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
PCT/US2018/059896 WO2019094642A1 (en) 2017-11-08 2018-11-08 T cell manufacturing compositions and methods
JP2022060497A JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2022060497A Division JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Publications (3)

Publication Number Publication Date
JP2024041873A JP2024041873A (ja) 2024-03-27
JP2024041873A5 true JP2024041873A5 (https=) 2024-04-03
JP7728373B2 JP7728373B2 (ja) 2025-08-22

Family

ID=66438061

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2020544357A Active JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
JP2022060497A Active JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法
JP2024001623A Active JP7728373B2 (ja) 2017-11-08 2024-01-10 T細胞を製造する組成物及び方法

Family Applications Before (2)

Application Number Title Priority Date Filing Date
JP2020544357A Active JP7054418B2 (ja) 2017-11-08 2018-11-08 T細胞を製造する組成物及び方法
JP2022060497A Active JP7420856B2 (ja) 2017-11-08 2022-03-31 T細胞を製造する組成物及び方法

Country Status (9)

Country Link
US (3) US11162072B2 (https=)
EP (1) EP3706784A4 (https=)
JP (3) JP7054418B2 (https=)
KR (2) KR20230008254A (https=)
CN (2) CN120519386A (https=)
BR (1) BR112020008927A2 (https=)
CA (1) CA3081840A1 (https=)
SG (1) SG11202004116QA (https=)
WO (1) WO2019094642A1 (https=)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018187515A1 (en) 2017-04-04 2018-10-11 Avidea Technologies, Inc. Peptide-based vaccines, methods of manufacturing, and uses thereof for inducing an immune response
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
BR112020025764A2 (pt) 2018-06-19 2021-05-11 Biontech Us Inc. neoantígenos e usos dos mesmos
KR20210040355A (ko) * 2018-06-19 2021-04-13 바이오엔테크 유에스 인크. 네오항원 및 이의 용도
CA3132028A1 (en) 2019-03-30 2020-10-08 Biontech Us Inc. Compositions and methods for preparing t cell compositions and uses thereof
TWI777160B (zh) * 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
GB201911066D0 (en) 2019-08-02 2019-09-18 Achilles Therapeutics Ltd T cell therapy
CN110514845B (zh) * 2019-08-22 2022-09-27 深圳新合睿恩生物医疗科技有限公司 一种肿瘤新生抗原免疫原性检测方法及检测平台
CA3162703A1 (en) * 2019-11-27 2021-06-03 Myst Therapeutics, Llc Method of producing tumor-reactive t cell composition using modulatory agents
JP2023505726A (ja) 2019-12-12 2023-02-10 アキレス セラピューティクス ユーケー リミテッド 配列決定のための核酸を得る方法
GB201918290D0 (en) 2019-12-12 2020-01-29 Achilles Therapeutics Ltd Method
WO2021219990A1 (en) 2020-04-28 2021-11-04 Achilles Therapeutics Uk Limited T cell therapy
US12365871B2 (en) 2020-04-28 2025-07-22 Lyell Immunopharma, Inc. Methods for culturing cells
EP4146794A1 (en) * 2020-05-04 2023-03-15 Iovance Biotherapeutics, Inc. Processes for production of tumor infiltrating lymphocytes and uses of the same in immunotherapy
AU2021325082A1 (en) 2020-08-13 2023-04-20 Biontech Us Inc. RAS neoantigens and uses thereof
US20230374455A1 (en) 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
AU2021388167A1 (en) * 2020-11-25 2023-07-06 Geneius Biotechnology, Inc. Antigen specific t cells and methods of making and using same
MX2023007003A (es) 2020-12-14 2023-08-18 Biontech Us Inc Antigenos especificos de tejidos para la inmunoterapia del cancer.
EP4320435A1 (en) 2021-04-09 2024-02-14 Achilles Therapeutics UK Limited Batch release assay for pharmaceutical products relating to t cell therapies
GB202109886D0 (en) 2021-07-08 2021-08-25 Achilles Therapeutics Uk Ltd Assay
IL312121A (en) * 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
GB202210006D0 (en) 2022-07-07 2022-08-24 Achilles Therapeutics Uk Ltd Analysis of T cell samples
AU2024234571A1 (en) * 2023-03-15 2025-09-25 Gaia Biomedicine Inc. Solution for suspending cells and use thereof
WO2025245492A1 (en) * 2024-05-24 2025-11-27 Biontech Us Inc. Compositions and methods for t cell manufacturing and uses thereof

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9022788D0 (en) 1990-10-19 1990-12-05 Cortecs Ltd Pharmaceutical formulations
PT633929E (pt) 1992-04-01 2004-07-30 Merix Bioscience Inc Metodo para proliferacao (in vitro) de precursores de celulas dentifricas e sua utilizacao para produzir imunogenios
AU4998993A (en) 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
CN1118572A (zh) 1993-03-05 1996-03-13 萨依特尔有限公司 Hla-a2.1组合肽及其用途
US5849589A (en) 1996-03-11 1998-12-15 Duke University Culturing monocytes with IL-4, TNF-α and GM-CSF TO induce differentiation to dendric cells
US6406705B1 (en) 1997-03-10 2002-06-18 University Of Iowa Research Foundation Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant
WO2004022709A2 (en) 2002-09-06 2004-03-18 Mannkind Corporation Epitope sequences
US7276478B2 (en) * 2003-09-25 2007-10-02 Zymogenetics, Inc. Methods of treating autoimmune diseases using IL-21
WO2006015497A1 (en) * 2004-08-13 2006-02-16 Val-Chum, S.E.C. Methods of use of a dkk1 protein, immunogenic polypeptides thereof, nucleic acid encoding the dkk1 protein or polypeptides, or ligands thereof for detecting tumors; and for eliciting immune response against tumors
WO2006110582A1 (en) * 2005-04-08 2006-10-19 Xcyte Therapies, Inc. Compositions and methods for the treatment of burns and sepsis
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
ES2579762T3 (es) 2006-03-01 2016-08-16 Janssen Pharmaceutica N.V. Tratamiento del cáncer combinando agente linfo - reductor con CLTs y citoquinas
US9809797B2 (en) * 2007-10-03 2017-11-07 National Institutes Of Health (Nih) U.S. Dept. Of Health And Human Services (Dhhs) Division Of Extramural Inventions And Technology Enhanced generation of cytotoxic T-lymphocytes by IL-21 mediated FOXP3 suppression
BR112012029066A2 (pt) 2010-05-14 2020-09-01 The General Hospital Corporation composições e processos de identificação de neoantígenos específicos de tumor.
WO2012159643A1 (en) 2011-05-24 2012-11-29 Biontech Ag Individualized vaccines for cancer
EP2749639B1 (en) 2012-02-10 2016-10-12 Hakushinkouseikai Foundation Proliferating agent for monocyte, culture medium for proliferating monocyte, method for producing monocyte, method for producing dendritic cell, and method for producing dendritic cell vaccine
US20150104441A1 (en) 2013-10-11 2015-04-16 Oslo Universitetssykehus Hf Identification of disease-driving antigens
EP3082853A2 (en) 2013-12-20 2016-10-26 The Broad Institute, Inc. Combination therapy with neoantigen vaccine
JP6661544B2 (ja) * 2014-04-24 2020-03-11 ミルテニイ バイオテック ゲゼルシャフト ミット ベシュレンクテル ハフツング 遺伝子改変したt細胞の自動生成法
CN103923880B (zh) * 2014-05-08 2016-03-30 成都百赛泰科生物科技有限公司 一种高效增殖、靶向杀伤肿瘤的ctl制备方法
US10973894B2 (en) 2014-10-02 2021-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Methods of isolating T cells having antigenic specificity for a cancer-specific mutation
WO2016180852A1 (en) * 2015-05-12 2016-11-17 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for preparing antigen-specific t cells from an umbilical cord blood sample
AU2016297014B2 (en) 2015-07-21 2021-06-17 Novartis Ag Methods for improving the efficacy and expansion of immune cells
AU2016306408B2 (en) 2015-08-10 2021-02-11 Toray Industries, Inc. Immune inducer
WO2017044661A1 (en) 2015-09-09 2017-03-16 Immune Design Corp. Ny-eso-1 specific tcrs and methods of use thereof
EP3347051A4 (en) 2015-09-10 2019-04-24 Affigen, Inc. SEQUENCING SELECTING TUMOR THEROSTICAS
CN109153727A (zh) 2016-04-15 2019-01-04 酵活有限公司 靶向免疫治疗剂的多特异性抗原结合构建体
EP3446119A1 (en) 2016-04-18 2019-02-27 The Broad Institute Inc. Improved hla epitope prediction
US11236145B2 (en) 2017-03-23 2022-02-01 Immatics Biotechnologies Gmbh T cell receptors and immune therapy using the same against PRAME positive cancers
AU2018337960B2 (en) 2017-09-20 2025-08-14 Neximmune, Inc. Cell compositions comprising antigen-specific T cells for adoptive therapy
CA3081840A1 (en) 2017-11-08 2019-05-16 Neon Therapeutics, Inc. T cell manufacturing compositions and methods
WO2020047449A2 (en) 2018-08-31 2020-03-05 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AU2019404547B2 (en) 2018-12-21 2025-01-30 Biontech Us Inc. Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells
TWI777160B (zh) 2019-05-08 2022-09-11 美商百歐恩泰美國公司 T細胞製備組合物及方法
US20230374455A1 (en) 2020-08-13 2023-11-23 Biontech Us Inc. T cell manufacturing compositions and methods
IL312121A (en) 2021-10-15 2024-06-01 Biontech Us Inc T cell manufacturing compositions and methods
IL321246A (en) 2022-12-09 2025-08-01 Biontech Us Inc Compositions and methods for producing T cells

Similar Documents

Publication Publication Date Title
JP2024041873A5 (https=)
JP2021502414A5 (https=)
Zhu T helper cell differentiation, heterogeneity, and plasticity
Sallusto et al. From vaccines to memory and back
Walker et al. De novo generation of antigen-specific CD4+ CD25+ regulatory T cells from human CD4+ CD25–cells
Thoman et al. Cell-mediated immunity in aged mice: an underlying lesion in IL 2 synthesis.
JP5184732B2 (ja) T細胞亜集団に特異的なモノクローナル抗体およびポリクローナル抗体の組成物および使用方法
JP2021520849A5 (https=)
Förster et al. Analysis of orbital T cells in thyroid-associated ophthalmopathy
JP2024038503A5 (https=)
JP4714767B2 (ja) ヒト血液由来のcd4+cd25+調節t細胞
Monsurrò et al. Quiescent phenotype of tumor-specific CD8+ T cells following immunization
JP2021505168A5 (https=)
CN109715788A (zh) 用于免疫疗法的t细胞组合物
Kyte et al. T cell responses in melanoma patients after vaccination with tumor-mRNA transfected dendritic cells
Nagorsen et al. Cytokine and chemokine expression profiles of maturing dendritic cells using multiprotein platform arrays
US20230357718A1 (en) Methods and materials for expanding antigen-specific t cells in culture
Tjoa et al. Dendritic cell-based immunotherapy for prostate cancer
Gilliet et al. Intranodal injection of semimature monocyte-derived dendritic cells induces T helper type 1 responses to protein neoantigen
Kimura et al. The regulatory role of heat shock protein 70-reactive CD4+ T cells during rat listeriosis.
JP2021534785A5 (https=)
US20030134341A1 (en) Th1 cell adoptive immunotherapy
Ferlazzo Natural killer and dendritic cell liaison: recent insights and open questions
JP2022500034A (ja) 抗原特異的tリンパ球ならびに抗原特異的tリンパ球を作製および使用する方法
CN101126076A (zh) TGF-β诱导的调节T细胞及其形成方法和应用